Literature DB >> 3931319

The action of antituberculosis drugs in short-course chemotherapy.

D A Mitchison.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 3931319     DOI： 10.1016/0041-3879(85)90040-6

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  137 in total

1.  Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.

Authors:  R S Wallis; M Phillips; J L Johnson; L Teixeira; L M Rocha; E Maciel; L Rose; C Wells; M Palaci; R Dietze; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Treatment of tuberculosis in Haiti.

Authors:  R Long; M Scalcini; J Ollé-Goig
Journal:  Am J Public Health       Date:  2001-10       Impact factor: 9.308

4.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

5.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

Review 6.  Osteomyelitis. Common causes and treatment recommendations.

Authors:  D R Dirschl; L C Almekinders
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

7.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

8.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.

Authors:  Moses Njire; Na Wang; Bangxing Wang; Yaoju Tan; Xingshan Cai; Yanwen Liu; Julius Mugweru; Jintao Guo; H M Adnan Hameed; Shouyong Tan; Jianxiong Liu; Wing Wai Yew; Eric Nuermberger; Gyanu Lamichhane; Jinsong Liu; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

10.  Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.

Authors:  José Francisco García-Rodríguez; N Valcarce-Pardeiro; H Álvarez-Díaz; A Mariño-Callejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-03       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.